stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Book value per share
Kiniksa Pharmaceuticals International, plc's book value per share at the end of fiscal 2025 was 7.6×, up 24.6% from 6.1× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 9.1×. Over the past ten years it has ranged from 2.7× (fiscal 2021) to 207× (fiscal 2016); the current reading is higher than 70% of that period. Kiniksa Pharmaceuticals International, plc ranks 18th of 84 Drug Manufacturers Specialty & Generic companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 7.6× | 24.62% |
| FY2024 | 6.1× | (2.00%) |
| FY2023 | 6.3× | 9.70% |
| FY2022 | 5.7× | 111.61% |
| FY2021 | 2.7× | (46.51%) |
| FY2020 | 5.0× | 20.94% |
| FY2019 | 4.2× | (55.87%) |
| FY2018 | 9.5× | (43.09%) |
| FY2017 | 16.6× | (91.98%) |
| FY2016 | 207× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 9.1× | 7.71% |
| Jun 2026 | 8.4× | 6.52% |
| Mar 2026 | 7.9× | 3.48% |
| Dec 2025 | 7.6× | 6.75% |
| 34 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | 20.8× |
| ELAN Elanco Animal Health Incorporated compare | 13.2× |
| ALKS Alkermes plc compare | 11.1× |
| KNSA Kiniksa Pharmaceuticals International, plc | 9.1× |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.9× |
| LQDA Liquidia Corporation compare | 2.2× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 1.6× |
| HIMS Hims & Hers Health, Inc. compare | 1.4× |
| SUPN Indivior Pharmaceuticals Inc. compare | −0.5× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement